OBJECTIVE: The Heart Rhythm Society, European Heart Rhythm Association, and European Cardiac Arrhythmia Society jointly recommend indefinite warfarin anticoagulation in patients with CHADS2 (congestive heart failure, hypertension, age, diabetes, and stroke) score of at least 2 who have undergone ablation for atrial fibrillation. This study determined the impact of CHADS2 score on risk of late stroke or transient ischemic attack after the performance of a surgical Cox maze procedure. METHODS: A retrospective review of 433 patients who underwent a Cox maze procedure at our institution was conducted. Three months after surgery, warfarin was discontinued regardless of CHADS2 score if the patient showed no evidence of atrial fibrillation, was off antiarrhythmic medications, and had no other indication for anticoagulation. A follow-up questionnaire was used to determine whether any neurologic event had occurred since surgery. RESULTS: Follow-up was obtained for 90% of the study group (389/433) at a mean of 6.6 ± 5.0 years. Among these patients, 32% (125/389) had a CHADS2 score of at least 2, of whom only 40% (51/125) remained on long-term warfarin after surgery. Six patients had late neurologic events (annualized risk of 0.2%). Neither CHADS2 score nor warfarin anticoagulation was significantly associated with the occurrence of late neurologic events. Among the individual CHADS2 criteria, both diabetes mellitus and previous stroke or transient ischemic attack were predictive of late neurologic events. CONCLUSIONS: The risk of stroke or transient ischemic attack in patients after a surgical Cox maze procedure was low and not associated with CHADS2 score or warfarin use. Given the known risks of warfarin, we recommend discontinuation of anticoagulation 3 months after the procedure if the patient has no evidence of atrial fibrillation, has discontinued antiarrhythmic medications, and is without any other indication for systemic anticoagulation.
OBJECTIVE: The Heart Rhythm Society, European Heart Rhythm Association, and European Cardiac Arrhythmia Society jointly recommend indefinite warfarin anticoagulation in patients with CHADS2 (congestive heart failure, hypertension, age, diabetes, and stroke) score of at least 2 who have undergone ablation for atrial fibrillation. This study determined the impact of CHADS2 score on risk of late stroke or transient ischemic attack after the performance of a surgical Cox maze procedure. METHODS: A retrospective review of 433 patients who underwent a Cox maze procedure at our institution was conducted. Three months after surgery, warfarin was discontinued regardless of CHADS2 score if the patient showed no evidence of atrial fibrillation, was off antiarrhythmic medications, and had no other indication for anticoagulation. A follow-up questionnaire was used to determine whether any neurologic event had occurred since surgery. RESULTS: Follow-up was obtained for 90% of the study group (389/433) at a mean of 6.6 ± 5.0 years. Among these patients, 32% (125/389) had a CHADS2 score of at least 2, of whom only 40% (51/125) remained on long-term warfarin after surgery. Six patients had late neurologic events (annualized risk of 0.2%). Neither CHADS2 score nor warfarin anticoagulation was significantly associated with the occurrence of late neurologic events. Among the individual CHADS2 criteria, both diabetes mellitus and previous stroke or transient ischemic attack were predictive of late neurologic events. CONCLUSIONS: The risk of stroke or transient ischemic attack in patients after a surgical Cox maze procedure was low and not associated with CHADS2 score or warfarin use. Given the known risks of warfarin, we recommend discontinuation of anticoagulation 3 months after the procedure if the patient has no evidence of atrial fibrillation, has discontinued antiarrhythmic medications, and is without any other indication for systemic anticoagulation.
Authors: Sakis Themistoclakis; Andrea Corrado; Francis E Marchlinski; Pierre Jais; Erica Zado; Antonio Rossillo; Luigi Di Biase; Robert A Schweikert; Walid I Saliba; Rodney Horton; Prasant Mohanty; Dimpi Patel; David J Burkhardt; Oussama M Wazni; Aldo Bonso; David J Callans; Michel Haissaguerre; Antonio Raviele; Andrea Natale Journal: J Am Coll Cardiol Date: 2010-02-23 Impact factor: 24.094
Authors: Donald Lloyd-Jones; Robert J Adams; Todd M Brown; Mercedes Carnethon; Shifan Dai; Giovanni De Simone; T Bruce Ferguson; Earl Ford; Karen Furie; Cathleen Gillespie; Alan Go; Kurt Greenlund; Nancy Haase; Susan Hailpern; P Michael Ho; Virginia Howard; Brett Kissela; Steven Kittner; Daniel Lackland; Lynda Lisabeth; Ariane Marelli; Mary M McDermott; James Meigs; Dariush Mozaffarian; Michael Mussolino; Graham Nichol; Véronique L Roger; Wayne Rosamond; Ralph Sacco; Paul Sorlie; Véronique L Roger; Randall Stafford; Thomas Thom; Sylvia Wasserthiel-Smoller; Nathan D Wong; Judith Wylie-Rosett Journal: Circulation Date: 2009-12-17 Impact factor: 29.690
Authors: Timo Weimar; Marci S Bailey; Yoshiyuki Watanabe; Donna Marin; Hersh S Maniar; Richard B Schuessler; Ralph J Damiano Journal: J Interv Card Electrophysiol Date: 2011-02-22 Impact factor: 1.900
Authors: Karen L Furie; Scott E Kasner; Robert J Adams; Gregory W Albers; Ruth L Bush; Susan C Fagan; Jonathan L Halperin; S Claiborne Johnston; Irene Katzan; Walter N Kernan; Pamela H Mitchell; Bruce Ovbiagele; Yuko Y Palesch; Ralph L Sacco; Lee H Schwamm; Sylvia Wassertheil-Smoller; Tanya N Turan; Deidre Wentworth Journal: Stroke Date: 2010-10-21 Impact factor: 7.914
Authors: Lindsey L Saint; Ralph J Damiano; Phillip S Cuculich; Tracey J Guthrie; Marc R Moon; Nabil A Munfakh; Hersh S Maniar Journal: J Thorac Cardiovasc Surg Date: 2013-08-30 Impact factor: 5.209
Authors: Chawannuch Ruaengsri; Matthew R Schill; Ali J Khiabani; Richard B Schuessler; Spencer J Melby; Ralph J Damiano Journal: Eur J Cardiothorac Surg Date: 2018-04-01 Impact factor: 4.191
Authors: Jason O Robertson; Anson M Lee; Rochus K Voeller; Marci S Damiano; Richard B Schuessler; Ralph J Damiano Journal: Eur J Cardiothorac Surg Date: 2014-02-11 Impact factor: 4.191